Intercept Pharmaceuticals, Inc.

Ladies and gentlemen, thank you for standing by and welcome to the Q3 2021 Intercept Pharmaceuticals earnings call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you need to press star 1 on your telephone. If you require any further assistance, please press star 0. I would now like to turn the call over to your host, Lisa DeFrancisco, SVP Investor Relations and Corporate Affairs. You may begin.

Thank you. Good morning, and thank you for joining us on today's call.

This morning, we issued a press release announcing our third quarter 2021 results and financial position, which is available on our website at www.interceptpharma.com. Before we begin our discussion, I'd like to note that during our call, we will be making forward-looking statements, including statements regarding our approved products and clinical development programs, certain regulatory matters, and our strategy prospects, financial guidance, and future commercial and financial performance. Listeners are cautioned not to place under reliance on these forward-looking statements which speak only as of the date of this call, and we undertake no obligation to update such statements except as required by law. These forward-looking statements are based on estimates and assumptions that, although believed to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties. Some, but not necessarily all, of the risk factors that could cause our actual results to differ materially from our historical results or those anticipated or predicted by our forward-looking statements are discussed in this morning's press release and in our periodic public filings with the SEC. Today's call will begin with prerecorded prepared remarks from our President and CEO, Jerry Durso, our Chief Commercial Officer, Linda Richardson, President of Research and Development and Chief Medical Officer, Dr. Michelle Berry, and Chief Financial Officer, Andrew Sake. Additionally, available today for Q&A purposes are Dr. Gail Cockwell, Senior Vice President, Medical Affairs, Safety and Pharmacovigilance, and Dr. Paul Nishman, Senior Vice President, Regulatory Affairs. Please limit yourself to one initial question in order to allow time for all questions to be addressed. Let me now turn the call over to our CEO, Jerry Durso. Jerry?